

Senfina is committed to enhancing human life
with technology and compassionate innovation



ABOUT

SENFINA is a leading pharmaceutical technology company, aiming to become global full service CDMO manufacturer for vaccines and other pharmaceutical forms



New Standard in CDMO Services

Innovative capabilities, processes and design, specifically designed for vaccines and other pharmaceutical forms
Modular production design that allows a new level of flexibility and quality Sophisticated design allows production licensing to external partners, making local production in emerging markets feasible

A Wealth of Experience

Decades of experience with legacy companies and international senior leadership Highly capable team with strong track record in pharmaceutical companies and CDMO services Established relationships with key public health stakeholders and customers

Compelling Financial Proposition

Significant order book already secured prior to capital investment Early focus on capital investment in infrastructure offers low-risk investment opportunity Attractive stock price offering with rapid roadmap to IPO

STAKEHOLDER

Decades of history and key relationships with stakeholders


~



PRODUCTION

Modular production design allows products to be completed in local emerging markets

Senfina remote production licenses allow local partners in emerging markets to establish “Fill and Finish” facilities






OFFERING

Comparison to other suppliers



	senfina	patheon	lonza	pci PHARMA SERVICES
FLEXIBLE MANUFACTURING TECHNOLOGY	✓			
EXCLUSIVE FOCUS ON VACCINES AND LIQUIDS	✓			
LOCALIZATION CAPABILITY IN EMERGING MARKETS	✓			
SWISS MANUFACTURING	✓	✓	✓	
INVESTMENT STAGE OF FIRM	Early-Stage firm Privately held Pre-Ipo	Established Company Subsidiary of large conglomerate	Established Company Publicly Traded	Established Company Private Equity Owned

STRATEGY AND OUTLOOK



Financials sending

Pre-orders and projected revenue



Senfina has secured several customers with an expected demand of 1.7 bio doses of vaccines from 2023 onward

A part of it is being covered by the operational trading company of Senfina, that originated from its originators, Synergy forte and Interport

1.7 bio
vaccine
doses

Orders already
secured for 2023+

150mm
Drug doses

Orders already
secured


ANNUAL NET REVENUE - ESTIMATES

- Phase 3 - Licensing
- Phase 3 - API
- Phase 2
- Phase 1




FINANCIALS SENDING

Total Revenue, Expenses & EBITDA between 2022-2036



FINANCIALS SENDING

Total Investment plan



Other Furniture	€ 56
Computer & IT	€ 20
Electric & Automation	€ 78
Energies & Equipment	€ 163
Licences & Permits	€ 403
Fees & Contingencies	€ 218
Buildings & HVAC	€ 473
Machinery	€ 537
General Site Investments	€ 120
TOTAL	€ 2,068

Total investment including acquisitions is **€ 2.1 BN**



CURRENT COMPANY VALUE
USD 3.8 B GBP 3.0 b

CURRENT SHARE PRICE
GBP 1.8

IPO PLANNED FOR
H2 2023 - H1 2024

2 PROJECTS ONGOING

3 PROJECTS PLANNED